The Biologics Patent Cliff: Inside Pharma’s 2026-2029 Reckoning
A four-year window will reshape biopharma: ten blockbuster biologics worth $136B in annual revenue face biosimilar competition between 2026 and 2029.
Patent Cliff
A four-year window will reshape biopharma: ten blockbuster biologics worth $136B in annual revenue face biosimilar competition between 2026 and 2029.